ストックスクリーナーアプリを入手
15.73
2.85%
0.29
前日終値:
$15.44
開ける：
$15.59
24時間の取引高:
64,927
Relative Volume:
1.03
時価総額：
$313.84M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+4.89%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$15.17
$16.22
1週間の範囲:
$14.85
$16.30
52週間の値動き範囲:
$13.36
$17.50
Lb Pharmaceuticals Inc Stock (LBRX) Company Profile
LBRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LBRX
Lb Pharmaceuticals Inc
|
15.61 | 346.52M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.68 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.20 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.14 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lb Pharmaceuticals Inc Stock (LBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-06 | 開始されました | Leerink Partners | Outperform |
| 2025-10-06 | 開始されました | Piper Sandler | Overweight |
| 2025-10-06 | 開始されました | Stifel | Buy |
Lb Pharmaceuticals Inc (LBRX) 最新ニュース
Analysts Set LB Pharmaceuticals Inc (NASDAQ:LBRX) PT at $30.50 - Defense World
LB Pharmaceuticals (NASDAQ:LBRX) Raised to Hold at Zacks Research - MarketBeat
LB Pharmaceuticals Inc (NASDAQ:LBRX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Biopharma financings climb to $18.7B in the third quarter - BioWorld MedTech
Q3 Earnings Forecast for LBRX Issued By Leerink Partnrs - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Stock Rating Upgraded by Leerink Partnrs - Defense World
September biopharma financings jump 54% to $7.12B - BioWorld MedTech
LB Pharmaceuticals (NASDAQ:LBRX) Upgraded at Leerink Partnrs - MarketBeat
LB Pharmaceuticals (NASDAQ:LBRX) Coverage Initiated by Analysts at Leerink Partners - Defense World
LB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative Symptoms - Sahm
Drug developer MapLight eyes $704.3 million valuation in US IPO - Reuters
LB Pharmaceuticals to Present Three Posters at 38th ECNP - GlobeNewswire
Leerink Partners Initiates LB Pharmaceuticals(LBRX.US) With Buy Rating, Announces Target Price $34 - 富途牛牛
Buy Rating for LB Pharmaceuticals Driven by Promising LB-102 and Market Potential - TipRanks
Leerink Partners Initiates LB Pharmaceuticals at Outperform With $34 Price Target - MarketScreener
0.66 effect size in cognition: LB Pharma's LB‑102 shows dose‑dependent gains; 3 ECNP posters Oct 11-14 - Stock Titan
LB Pharmaceuticals (NASDAQ:LBRX) Now Covered by Analysts at Leerink Partners - MarketBeat
LB Pharmaceuticals stock initiated at Outperform by Leerink Partners - Investing.com
Promising Prospects for LB Pharmaceuticals: Buy Rating Affirmed on LB-102’s Market Potential - TipRanks
Piper Sandler initiates coverage on LB Pharmaceuticals stock with Overweight rating - Investing.com
Stifel initiates coverage on LB Pharmaceuticals stock with Buy rating - Investing.com
LB Pharmaceuticals IncCommon Stock (Nasdaq:LBRX) Stock Quote - FinancialContent
LB Pharmaceuticals Appoints William Kane and Rekha Hemrajani To Board - citybiz
LB Pharmaceuticals adds two directors following Nasdaq debut By Investing.com - Investing.com Nigeria
LB Pharmaceuticals adds two directors following Nasdaq debut - Investing.com India
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani - The Manila Times
Strategic Board Expansion: LB Pharmaceuticals Strengthens Leadership for Phase 3 Schizophrenia Drug Trial - Stock Titan
Scoop: Voltron Therapeutics plans IPO next year - Axios
Deep Track Capital, LP Acquires Significant Stake in LB Pharmaceuticals Inc - GuruFocus
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in LB Pha - GuruFocus
COMMODORE CAPITAL LP Acquires 1,225,000 Shares in LB Pharmaceuti - GuruFocus
Deep Track Capital, LP Acquires Significant Stake in LB Pharmace - GuruFocus
LB Pharmaceuticals (NASDAQ:LBRX) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Big Pharma-backed MapLight plots IPO to advance neuro pipeline - Fierce Biotech
Novo-Backed Drug Developer MapLight Therapeutics Files for IPO - Bloomberg.com
Neuro drug developer LB Pharma seeks $300M+ valuation in U.S. IPO - MSN
Layoff Tracker: Arsenal, X4 Lay Off Half of Staff to Cut Costs - BioSpace
Hedge Fund and Insider Trading News: Ray Dalio, Bill Ackman, Warren Buffett, Steve Cohen, Mario Gabelli, Balyasny Asset Management, LB Pharmaceuticals Inc (LBRX), Avista Corp (AVA), and More - Insider Monkey
Schizophrenia drug developer LB Pharma jumps in trading debut - MSN
Wednesday 9/17 Insider Buying Report: LBRX, RAPP - Nasdaq
Major Investors Make Bold Moves in LB Pharmaceuticals Stock! - TipRanks
Vida Ventures raises $5.0m in LB Pharmaceuticals (LBRX) By Investing.com - Investing.com Nigeria
LB Pharmaceuticals Launches $285 Million Initial Public Offering - Global Legal Chronicle
Vida Ventures raises $5.0m in LB Pharmaceuticals (LBRX) - Investing.com
Finance Watch: LB Pharmaceuticals Launches Second-Largest Biopharma IPO Of 2025 In The US - insights.citeline.com
Lb Pharmaceuticals Inc (LBRX) 財務データ
Lb Pharmaceuticals Inc (LBRX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Lb Pharmaceuticals Inc (LBRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Deep Track Biotechnology Maste | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
666,666 |
9,999,990 |
666,666 |
| Pontifax Management 4 G.P. (20 | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Nussbaum Ran | Director |
Sep 12 '25 |
Buy |
15.00 |
1,000,000 |
15,000,000 |
1,411,681 |
| Vida Ventures GP III, L.L.C. | 10% Owner |
Sep 12 '25 |
Buy |
15.00 |
333,333 |
4,999,995 |
880,214 |
1.10%
大文字化:
|
ボリューム (24 時間):